

Impact of Menstrual Blood Loss and Oral Contraceptive Use on Oxygen-carrying Capacity

MELISSA F. KELLER, MICHELLE L. HARRISON, and SOPHIE LALANDE

Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX

ABSTRACT

KELLER, M. F., M. L. HARRISON, and S. LALANDE. Impact of Menstrual Blood Loss and Oral Contraceptive Use on Oxygen-carrying Capacity. *Med. Sci. Sports Exerc.*, Vol. 52, No. 6, pp. 1414–1419, 2020. **Purpose:** The effect of menstrual blood loss on oxygen-carrying capacity remains equivocal. The purpose of this study was to determine the effect of menstrual blood loss on hemoglobin mass in young, healthy women. **Methods:** Twenty-one women (age, 23 ± 6 yr; height, 168 ± 7 cm; weight, 66.1 ± 12.6 kg) with regular menstrual cycles, either using ($n = 10$) or not using oral contraceptives, participated in the study. Hemoglobin mass was assessed using carbon monoxide rebreathing on three separate occasions over the course of one menstrual cycle. **Results:** Visits for women not using oral contraceptives were performed in the early follicular phase (3 ± 1 d after the onset of menses), late follicular phase (1 ± 1 d after the surge of luteinizing hormone in urine), and luteal phase (9 ± 1 d after the late follicular visit). Visits for women using oral contraceptives were performed in the early follicular phase (3 ± 1 d after the onset of menses), late follicular phase (15 ± 3 d after the onset of menses), and luteal phase (9 ± 2 d after the late follicular visit). Hemoglobin mass was not affected by menstrual cycle phase (early follicular, 618 ± 61 ; late follicular, 610 ± 65 ; luteal, 607 ± 68 g; $P = 0.52$). Interestingly, when normalized to weight, hemoglobin mass was 12% higher in women using oral contraceptives in comparison to nonusers (10.0 ± 1.2 vs 8.9 ± 1.2 g·kg⁻¹, $P < 0.05$). **Conclusion:** Menstrual blood loss had no measurable effect on hemoglobin mass in eumenorrheic women. However, oral contraceptive use resulted in a greater oxygen-carrying capacity, potentially leading to a greater maximal oxygen uptake. **Key Words:** HEMOGLOBIN MASS, MENSTRUAL CYCLE, EARLY FOLLICULAR, CARBON MONOXIDE REBREATHING

Regular menstrual blood loss, occurring during the early follicular phase of the menstrual cycle, ranges from 10 to 90 mL (1–3). Hemoglobin concentration, a common clinical marker of oxygen-carrying capacity, has been reported to either decrease (4–7) increase (8), or to not change (9–12) during the early follicular phase of the menstrual cycle. Variations in plasma volume, induced by changes in hydration status, posture during the blood draw, and fluid retention caused by oscillating progesterone and estradiol levels, contribute to these reports of varying hemoglobin concentration across the menstrual cycle (13,14). Moreover, hemoglobin concentration correlates only with a modest extent with red blood cell mass and therefore does not represent an optimal marker of oxygen-carrying capacity (15). Few studies have examined the effect of the menstrual cycle on red blood cell mass, and both reported that red blood cell mass remains

unchanged throughout the menstrual cycle (16,17). However, red blood cell mass was calculated using hematocrit levels, which are also influenced by changes in plasma volume (16), or measurements were made during the early follicular phase of the menstrual cycle in only 2 women (17).

Measures of hemoglobin mass, assessed via the carbon monoxide rebreathing technique, remain unaffected by variations in plasma volume and consequently better represent oxygen-carrying capacity (18). Hemoglobin mass has previously been assessed in elite female athletes over prolonged periods of time to determine the variation in hemoglobin mass throughout a training season (19,20). However, these studies did not control for menstrual cycle phase, as it was estimated that menstrual blood loss would fall within the mean coefficient of variation of 2.2% reported for different carbon monoxide rebreathing techniques. It was therefore assumed that this minimal variation in hemoglobin mass would have no significant effect on oxygen-carrying capacity (21). Although there was no significant change in hemoglobin mass over these prolonged periods of time, the observed coefficient of variation for hemoglobin mass was repeatedly larger than the commonly reported error of the technique (19,20), suggesting that other factors contributed to the observed variation in hemoglobin mass. Indeed, hemoglobin mass assessed during a competitive season of road cycling lasting several months varied by 3.3%, with individual variation ranging from 2.0% to 4.4% (20). Similarly, the within-subject coefficient of variation

Address for correspondence: Sophie Lalande, Ph.D., Department of Kinesiology and Health Education, The University of Texas at Austin, 2109 San Jacinto, UT Mail Code D3700, Austin, TX 78712; E-mail: sophie.lalande@austin.utexas.edu.

Submitted for publication September 2019.

Accepted for publication December 2019.

0195-9131/20/5206-1414/0

MEDICINE & SCIENCE IN SPORTS & EXERCISE®

Copyright © 2019 by the American College of Sports Medicine

DOI: 10.1249/MSS.0000000000002252

for hemoglobin mass measured several times over 1 yr was lower for men than for women (3.4% vs 4.0%, respectively) (19). Although the lower absolute hemoglobin mass observed in women partly explains the greater coefficient of variation, female athletes showed a greater SD of changes in hemoglobin mass over time in comparison to men athletes (19). Thus, the effect of menstrual blood loss on hemoglobin mass and consequently oxygen-carrying capacity remains equivocal. Therefore, the purpose of this study was to determine the effect of menstrual blood loss on hemoglobin mass in women with regular menstrual cycles. Women using and not using oral contraceptives were included in the study. We hypothesized that hemoglobin mass would not change across phases of the menstrual cycle.

METHODS

Study protocol. Healthy, eumenorrheic, nonsmoking women were recruited to participate in the study. All women provided informed written consent for participating in the study, which was approved by the institutional review board of the University of Texas at Austin. Hematological variables were assessed on three occasions throughout one menstrual cycle. Visits were scheduled in the early follicular phase (visit 1: 3–5 d after the onset of menses), late follicular phase (visit 2: 1–2 d after the surge of luteinizing hormone in urine), and luteal phase (9–10 d after visit 2) of the menstrual cycle. Eight days after the onset of menses, women started self-administering ovulation tests to detect luteinizing hormone in their urine. Tests were administered daily until positive for ovulation. Menstrual cycle phases were confirmed by measuring estradiol and progesterone levels from venous blood samples obtained on each visit. Visits for women using oral contraceptives were scheduled in the early follicular phase (visit 1: 3–5 d after the onset of menses), late follicular phase (visit 2: 14 d after the onset of menses), and luteal phase (visit 3: 9–10 d after visit 2) of the menstrual cycle. Average heart rate and blood pressure values were calculated from three measures obtained after 5 min of supine rest (Omron Healthcare, Inc., Lake Forest, IL).

Hematological variables. Hemoglobin mass, red blood cell volume, plasma volume, and total blood volume were determined using a modified version of the optimized carbon monoxide rebreathing technique (22,23). Participants laid in the supine position for 20 min before the start of the procedure to allow for stabilization of fluid movement between interstitial and intravascular spaces (24). A venous blood draw was first obtained to measure baseline levels for carboxyhemoglobin, hematocrit, and hemoglobin (ABL FLEX CO-OX, Radiometer, CA). The volume of carbon monoxide administered to each participant was then calculated based on body surface area and hemoglobin concentration (25). Carbon monoxide rebreathing was performed by introducing this bolus of carbon monoxide into a low-volume closed-circuit rebreathing system containing ambient air. The rebreathing system consisted of a 5-L anesthesia bag (Rusch Inc., Duluth, GA) connected to a four-way directional control valve (Hans Rudolph, Inc., Shawnee, KS).

Participants were switched from breathing ambient air to the rebreathing system at end-exhalation. The bolus of carbon monoxide was immediately introduced into the rebreathing system through a small port in the four-way directional control valve. Participants rebreathed this mixture of carbon monoxide and ambient air for a period of 2 min while maintaining a normal breathing pattern. A second venous blood draw was obtained 10 min after the start of the rebreathing to assess carboxyhemoglobin levels. Hemoglobin mass, red blood cell volume, plasma volume, and total blood volume were calculated from the change in carboxyhemoglobin levels induced by the carbon monoxide rebreathing using equations developed by Burge and Skinner (25). The molar amount of carbon monoxide was corrected by 2.2% to account for the amount of carbon monoxide remaining in the system following rebreathing (22,25,26). The coefficient of variation for hemoglobin mass, based on duplicate measures performed on consecutive days in five individuals, is 2.6% in our laboratory, similar to the commonly reported mean coefficient of variation of 2.2% for different carbon monoxide rebreathing techniques (21), and to the coefficient of variation of 1.7% reported for the optimized carbon monoxide rebreathing technique (23).

Estradiol, progesterone, and ferritin levels. To confirm menstrual phase in women not using oral contraceptives, a blood sample was obtained before the carbon monoxide rebreathing protocol. Venous blood was collected into a serum separator tube, and the serum was aliquoted and stored at -80°C for subsequent analyses. Once all samples were collected, concentrations of serum estradiol and progesterone were determined using MILLIPLEX MAP Multi-Species hormone magnetic bead panel (MilliporeSigma, Burlington, MA) and an enzyme-linked immunosorbent assay (BioVendor, Asheville, NC), respectively. Serum ferritin levels were determined using an enzyme-linked immunosorbent assay (BioVendor).

Statistical analysis. A repeated-measures analysis of variance was used to evaluate the effect of different phases of the menstrual cycle (early follicular, late follicular, and luteal) on all variables. A two-way repeated-measures analysis of variance was used to evaluate the effect of group (women using oral contraceptives vs women not using oral contraceptives) and phases of the menstrual cycle (early follicular, late follicular, and luteal). When appropriate, *post hoc* analyses were performed using Tukey's test. Significance was set at $P \leq 0.05$. All values are reported as mean \pm SD.

RESULTS

Twenty-one women (age, 23 ± 6 yr; height, 168 ± 7 cm) participated in the study. Serum ferritin levels were 19.5 ± 19.4 ng·mL $^{-1}$ for the group and were not correlated with hemoglobin concentration or hemoglobin mass. For women not using oral contraceptives, visit 1 took place 3 ± 1 d after the onset of menses, visit 2 took place 1 ± 1 d after a positive ovulation test result, and visit 3 took place 9 ± 1 d after visit 2. Estradiol and progesterone levels changed as expected across phases of the

menstrual cycle (estradiol: 43 ± 52 pg·mL⁻¹ for visit 1, 192 ± 213 pg·mL⁻¹ for visit 2, 92 ± 124 pg·mL⁻¹ for visit 3; progesterone: 0.3 ± 0.1 ng·mL⁻¹ for visit 1, 0.5 ± 0.2 ng·mL⁻¹ for visit 2, and 2.7 ± 2.8 ng·mL⁻¹ for visit 3; $P < 0.05$). For women using oral contraceptives, visit 1 took place 3 ± 1 d after the onset of menses, visit 2 took place 15 ± 3 d after menses, and visit 3 took place 9 ± 2 d after visit 2.

Effect of menstrual cycle phase. There was no effect of menstrual cycle phase on weight, systolic and diastolic blood pressure, hemoglobin level, or hematocrit level (Table 1). The menstrual cycle had a significant effect on heart rate, with a lower heart rate being observed in the early follicular phase in comparison to the luteal phase. Absolute hemoglobin mass and hemoglobin mass normalized to weight did not differ between menstrual cycle phases. Similarly, there was no difference in red blood cell volume, plasma volume, or total blood volume across phases of the menstrual cycle (Table 1).

Use of oral contraceptives. Ten of 21 women were using oral contraceptives. There was no difference in weight, body mass index, systolic and diastolic blood pressure, heart rate, and hemoglobin, hematocrit, and serum ferritin levels between women using oral contraceptives and women not using oral contraceptives (Table 2). Similarly, absolute hemoglobin mass, red blood cell volume along with plasma, and blood volume were not different between groups across phases of the menstrual cycle (Table 3). However, when normalized to weight, hemoglobin mass was greater in women using oral contraceptives in comparison to women not using oral contraceptives across phases of the menstrual cycle (10.0 ± 1.2 vs 8.9 ± 1.2 g·kg⁻¹, $P < 0.05$; Fig. 1).

DISCUSSION

The purpose of this study was to determine the effect of menstrual blood loss on hemoglobin mass in women with regular menstrual cycles. As hypothesized, there was no significant change in hemoglobin mass across phases of the menstrual cycle, indicating that regular menstrual blood loss does not affect oxygen-carrying capacity. The coefficient of variation for hemoglobin mass over the course of one menstrual cycle was 4.1%, which is above the coefficient of variation of 2.2% commonly reported for the carbon monoxide rebreathing technique but similar to the variability reported in elite female athletes over training seasons (19,20). Heart rate

TABLE 2. Characteristics of women not using oral contraceptives and women using oral contraceptives.

	No Oral Contraceptives (n = 11)	Oral Contraceptives (n = 10)
Weight (kg)	68.3 ± 15.0	64.1 ± 8.2
Body mass index (kg·m ⁻²)	24.5 ± 5.0	22.6 ± 2.4
Systolic blood pressure (mm Hg)	109 ± 10	113 ± 8
Diastolic blood pressure (mm Hg)	67 ± 8	72 ± 7
Heart rate (bpm)	64 ± 8	68 ± 9
Hemoglobin (g·dL ⁻¹)	12.8 ± 1.0	13.0 ± 1.0
Hematocrit (%)	39.3 ± 3.0	40.0 ± 2.9
Serum ferritin (ng·mL ⁻¹)	21.6 ± 24.5	18.9 ± 11.7

was the only physiological variable affected by the menstrual cycle. Heart rate was lower in the early follicular phase in comparison to the luteal phase. Although most studies report no change in resting heart rate over the menstrual cycle, several others have reported a similarly increased heart rate during the midluteal phase (27), possibly due to increased body temperature (28).

A strong relation exists between hemoglobin mass and maximal oxygen uptake (18). Therefore, the observed lack of change in hemoglobin mass in this study supports previous literature demonstrating that maximal oxygen uptake does not change across phases of the menstrual cycle. Indeed, similar maximal oxygen uptakes were reported across phases of the menstrual cycle in sedentary and moderately active women, runners, cyclists, and triathletes (8,29–33). In contrast, Lebrun et al. (11) reported that maximal oxygen uptake was 1.9% lower in the midluteal compared with the follicular phase in 16 women with maximal oxygen uptake greater than 50 mL·kg⁻¹·min⁻¹. Although the mechanism behind this reduction remains unclear, the authors reported no difference in hemoglobin concentration between phases of the menstrual cycle.

Oxygen-carrying capacity and oral contraceptive use. Women with regular menstrual blood loss using or not using oral contraceptives were included in this study; thus, 10 of our 21 participants were using oral contraceptives. Interestingly, hemoglobin mass normalized to weight was higher in women using oral contraceptives compared with women not using oral contraceptives. This finding is important because the 1.1 g·kg⁻¹ difference in hemoglobin mass observed between groups theoretically corresponds to a difference in maximal oxygen uptake of approximately 4 mL·kg⁻¹·min⁻¹, and therefore implies a 12% greater maximal oxygen uptake in women using oral contraceptives vs women not using oral contraceptives (18). Oral contraceptive use decreases menstrual blood loss and increases serum iron levels, which may contribute to the greater oxygen-carrying capacity observed in women using oral contraceptives. A regular menstrual cycle represents a loss of 5–40 mg of iron, a mineral essential to erythropoiesis (34), with each menstruation (35). Menstrual blood loss decreases by half after 6 months of oral contraceptive use (36), representing a consistently smaller loss of iron each month. Consequently, increased serum iron levels are reported for oral contraceptive users when compared with nonoral contraceptive users (37). Serum ferritin levels, an indicator of iron status, were reported to increase with oral contraceptive use (38) or to not change after 6 months of oral

TABLE 1. Participant characteristics across phases of the menstrual cycle.

	Early Follicular	Late Follicular	Luteal
Weight (kg)	66.1 ± 12.6	66.3 ± 12.4	66.4 ± 12.6
Systolic blood pressure (mm Hg)	113 ± 9	110 ± 10	111 ± 9
Diastolic blood pressure (mm Hg)	71 ± 8	68 ± 7	70 ± 9
Heart rate (bpm)	62 ± 8	67 ± 10	68 ± 7 ^a
Hemoglobin (g·dL ⁻¹)	13.0 ± 1.2	12.8 ± 0.9	12.9 ± 0.9
Hematocrit (%)	40.1 ± 3.5	39.4 ± 2.6	39.5 ± 2.6
Hemoglobin mass (g)	618 ± 61	610 ± 65	607 ± 68
Hemoglobin mass (g·kg ⁻¹)	9.5 ± 1.3	9.4 ± 1.2	9.3 ± 1.4
Red blood cell volume (mL)	1896 ± 188	1874 ± 200	1865 ± 208
Plasma volume (mL)	3345 ± 565	3375 ± 466	3328 ± 425
Blood volume (mL)	5241 ± 702	5249 ± 621	5194 ± 582

^aDifferent between early follicular and luteal phase.

TABLE 3. Hematological variables in women using and not using oral contraceptives across phases of the menstrual cycle.

	No Oral Contraceptives (<i>n</i> = 11)			Oral Contraceptives (<i>n</i> = 10)		
	Early Follicular	Late Follicular	Luteal	Early Follicular	Late Follicular	Luteal
Hemoglobin mass (g)	604 ± 69	588 ± 68	590 ± 74	632 ± 51	635 ± 55	626 ± 57
Red blood cell volume (mL)	1855 ± 212	1805 ± 208	1813 ± 227	1941 ± 156	1950 ± 169	1923 ± 178
Plasma volume (mL)	3322 ± 552	3270 ± 457	3276 ± 396	3371 ± 608	3491 ± 472	3386 ± 470
Blood volume (mL)	5176 ± 713	5075 ± 609	5089 ± 557	5312 ± 721	5440 ± 605	5308 ± 617

contraceptive use, despite the reduced menstrual blood loss (36). In the present study, there was no difference in average serum ferritin levels between oral contraceptive users and nonusers. However, depleted iron stores (serum ferritin levels <15 ng·mL⁻¹) were observed in seven women not using oral contraceptives, whereas only two women using oral contraceptives had depleted iron stores. Thus, a chronically reduced menstrual blood loss in conjunction with adequate iron availability potentially contributed to the observed greater hemoglobin mass normalized to weight in women using oral contraceptives.

Our observation of a greater oxygen-carrying capacity, and a possibly greater maximal oxygen uptake, with oral contraceptive use contradicts reports of either a lack of effect or a negative effect of oral contraceptives on maximal oxygen uptake. Indeed, several studies have reported either no change (31,39) or decreases (32,40–42) in maximal oxygen uptake with the use of oral contraceptives. Four months of oral contraceptive use decreased peak aerobic capacity by 11% in six moderately active, eumenorrheic women (32). The authors concluded that a reduced oxygen-carrying capacity was not responsible for the reduced peak aerobic capacity because hemoglobin concentration remained unchanged with oral contraceptive use. However, oral contraceptive use increases the activity of the renin–angiotensin–aldosterone system (43), which leads to an increase in plasma volume, which could have masked an increase in hemoglobin mass in these women. Moreover, without a compensatory increase in hemoglobin mass, a decreased hemoglobin concentration would have instead been observed after an increase in plasma volume. Accordingly, Lebrun et al. (41) reported a 4.7% decreased maximal oxygen uptake in the second month of oral contraceptive use in seven highly active women. The observed reduction in maximal oxygen uptake was not linked to alterations in oxygen-carrying capacity of the blood because hemoglobin concentration, mean red cell volume, and hematocrit levels did not differ significantly over 6 wk of oral contraceptive use. In contrast, our findings suggest an increase in maximal oxygen uptake owing to an increased oxygen-carrying capacity with oral contraceptive use. Oral contraceptive use may therefore have deleterious effects on maximal oxygen uptake despite an increased oxygen-carrying capacity. In summary, conclusions on the effect of oral contraceptive use on maximal oxygen uptake are currently limited by studies with small sample sizes, a wide range of testing protocols, and varying types and durations of oral contraceptive use.

Because the main objective of the present study was to determine the effect of menstrual blood loss on hemoglobin mass

in women with regular menstrual cycles, no distinction was made between women using and not using oral contraceptives, or regarding the type and duration of oral contraceptive use. Participants had an average hemoglobin concentration of 12.9 g·dL⁻¹. Thus, the 10- to 90-mL blood loss associated with a regular menstrual cycle (1–3) would correspond to a 1- to 12-g reduction in hemoglobin mass in our participants. The group average hemoglobin mass of 612 g in combination with our established coefficient of variation of 2.6% resulted in a typical error of approximately 16 g in the measure of hemoglobin mass. Therefore, the potentially larger variation in hemoglobin mass associated with the carbon monoxide rebreathing technique than with menstrual blood loss limited our ability to detect a significant change in hemoglobin mass across phases of one menstrual cycle. Nevertheless, a difference in hemoglobin mass normalized to weight was detected between women using and women not using oral contraceptives. Physical activity levels were not specifically assessed, but all our participants were recreationally active women. Although there was no difference in weight or body mass index between women using and women not using oral contraceptives, assessment of lean body mass would have resulted in a more precise normalization of hemoglobin mass. In conclusion, menstrual blood loss did not affect hemoglobin mass in a physiologically relevant manner over the course of one menstrual cycle in eumenorrheic women. Hemoglobin mass, when normalized to weight, was 12% greater in women using oral contraceptives, possibly due to the reduced menstrual blood loss in conjunction




FIGURE 1—Hemoglobin mass normalized to weight across phases of the menstrual cycle in women using oral contraceptives (black bars) and women not using oral contraceptives (white bars). *Different between women using and not using oral contraceptives.

with adequate iron availability. Therefore, the use of oral contraceptives resulted in a greater oxygen-carrying capacity, which could potentially lead to a greater maximal oxygen uptake.

We would like to thank Dr. Nina Stachenfeld for her guidance in the assessment of menstrual cycle phase in our participants. The results of

this study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation. The results of the present study do not constitute endorsement by the American College of Sports Medicine.

The authors do not have any conflict of interest. This work was supported by a Small Research Grant from the College of Education of the University of Texas at Austin.

REFERENCES

1. Baldwin RM, Whalley PJ, Pritchard JA. Measurements of menstrual blood loss. *Am J Obstet Gynecol*. 1961;81:739–42.
2. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss—a population study. Variation at different ages and attempts to define normality. *Acta Obstet Gynecol Scand*. 1966;45(3):320–51.
3. Fraser IS, Warner P, Marantos PA. Estimating menstrual blood loss in women with normal and excessive menstrual fluid volume. *Obstet Gynecol*. 2001;98(5 Pt 1):806–14.
4. Kim I, Yetley EA, Calvo MS. Variations in iron-status measures during the menstrual cycle. *Am J Clin Nutr*. 1993;58(5):705–9.
5. Vellar OD. Changes in hemoglobin concentration and hematocrit during the menstrual cycle. I. A cross-sectional study. *Acta Obstet Gynecol Scand*. 1974;53(3):243–6.
6. Javaid A, Hasan R, Naim T. A comparative study of body weight, hemoglobin concentration and hematocrit during follicular and luteal phases of menstrual cycle. *J Med Sci*. 2007;7:146–9.
7. Jurkowski JE, Jones NL, Toews CJ, Sutton JR. Effects of menstrual cycle on blood lactate, O₂ delivery, and performance during exercise. *J Appl Physiol Respir Environ Exerc Physiol*. 1981;51(6):1493–9.
8. Dombovy ML, Bonekat HW, Williams TJ, Staats BA. Exercise performance and ventilatory response in the menstrual cycle. *Med Sci Sports Exerc*. 1987;19(2):111–7.
9. Claybaugh JR, Sato AK, Crosswhite LK, Hassell LH. Effects of time of day, gender, and menstrual cycle phase on the human response to a water load. *Am J Physiol Regul Integr Comp Physiol*. 2000;279(3):R966–73.
10. Hackney AC, McCracken-Compton MA, Ainsworth B. Substrate responses to submaximal exercise in the midfollicular and midluteal phases of the menstrual cycle. *Int J Sport Nutr*. 1994;4(3):299–308.
11. Lebrun CM, McKenzie DC, Prior JC, Taunton JE. Effects of menstrual cycle phase on athletic performance. *Med Sci Sports Exerc*. 1995;27(3):437–44.
12. Belza A, Ersboll AK, Henriksen M, Thilsted SH, Tetens I. Day-to-day variation in iron-status measures in young iron-deplete women. *Br J Nutr*. 2005;94(4):551–6.
13. Berkow L. Factors affecting hemoglobin measurement. *J Clin Monit Comput*. 2013;27(5):499–508.
14. Stachenfeld NS. Sex hormone effects on body fluid regulation. *Exerc Sport Sci Rev*. 2008;36(3):152–9.
15. Murphy WG. The sex difference in haemoglobin levels in adults—mechanisms, causes, and consequences. *Blood Rev*. 2014;28(2):41–7.
16. Chapman AB, Zamudio S, Woodmansee W, et al. Systemic and renal hemodynamic changes in the luteal phase of the menstrual cycle mimic early pregnancy. *Am J Physiol*. 1997;273(5 Pt 2):F777–82.
17. Fortney SM, Turner C, Steinmann L, Driscoll T, Alfrey C. Blood volume responses of men and women to bed rest. *J Clin Pharmacol*. 1994;34(5):434–9.
18. Schmidt W, Prommer N. Impact of alterations in total hemoglobin mass on VO₂max. *Exerc Sport Sci Rev*. 2010;38(2):68–75.
19. Eastwood A, Sharpe K, Bourdon PC, et al. Within-subject variation in hemoglobin mass in elite athletes. *Med Sci Sports Exerc*. 2012;44(4):725–32.
20. Garvican LA, Martin DT, McDonald W, Gore CJ. Seasonal variation of haemoglobin mass in internationally competitive female road cyclists. *Eur J Appl Physiol*. 2010;109(2):221–31.
21. Gore CJ, Hopkins WG, Burge CM. Errors of measurement for blood volume parameters: a meta-analysis. *J Appl Physiol (1985)*. 2005;99(5):1745–58.
22. Lalande S, Kelsey JW, Joyner MJ, Johnson BD. Determination of blood volume by pulse CO-oximetry. *Physiol Meas*. 2012;33(1):19–27.
23. Schmidt W, Prommer N. The optimised CO-rebreathing method: a new tool to determine total haemoglobin mass routinely. *Eur J Appl Physiol*. 2005;95(5–6):486–95.
24. Jacob G, Raj SR, Ketch T, et al. Postural pseudoanemia: posture-dependent change in hematocrit. *Mayo Clin Proc*. 2005;80(5):611–4.
25. Burge CM, Skinner SL. Determination of hemoglobin mass and blood volume with CO: evaluation and application of a method. *J Appl Physiol*. 1995;79(2):623–31.
26. Gore CJ, Bourdon PC, Woolford SM, Ostler LM, Eastwood A, Scroop GC. Time and sample site dependency of the optimized co-rebreathing method. *Med Sci Sports Exerc*. 2006;38(6):1187–93.
27. Janse de Jonge XA. Effects of the menstrual cycle on exercise performance. *Sports Med*. 2003;33(11):833–51.
28. Jose AD, Stitt F, Collison D. The effects of exercise and changes in body temperature on the intrinsic heart rate in man. *Am Heart J*. 1970;79(4):488–98.
29. De Souza MJ, Maguire MS, Rubin KR, Maresh CM. Effects of menstrual phase and amenorrhea on exercise performance in runners. *Med Sci Sports Exerc*. 1990;22(5):575–80.
30. Dean TM, Perreault L, Mazzeo RS, Horton TJ. No effect of menstrual cycle phase on lactate threshold. *J Appl Physiol (1985)*. 2003;95(6):2537–43.
31. Bryner RW, Toffle RC, Ullrich IH, Yeater RA. Effect of low dose oral contraceptives on exercise performance. *Br J Sports Med*. 1996;30(1):36–40.
32. Casazza GA, Suh SH, Miller BF, Navazio FM, Brooks GA. Effects of oral contraceptives on peak exercise capacity. *J Appl Physiol (1985)*. 2002;93(5):1698–702.
33. Rechichi C, Dawson B, Goodman C. Oral contraceptive phase has no effect on endurance test. *Int J Sports Med*. 2008;29(4):277–81.
34. Hillman RS, Finch CA. Erythropoiesis. *N Engl J Med*. 1971;285(2):99–101.
35. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. *Br J Obstet Gynaecol*. 1990;97(8):734–9.
36. Larsson G, Milsom I, Lindstedt G, Rybo G. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. *Contraception*. 1992;46(4):327–34.
37. Frassinelli-Gunderson EP, Margen S, Brown JR. Iron stores in users of oral contraceptive agents. *Am J Clin Nutr*. 1985;41(4):703–12.
38. Milman N, Kirchhoff M, Jorgensen T. Iron status markers, serum ferritin and hemoglobin in 1359 Danish women in relation to menstruation, hormonal contraception, parity, and postmenopausal hormone treatment. *Ann Hematol*. 1992;65(2):96–102.

39. Rebelo AC, Zuttin RS, Verlengia R, Cesar Mde C, de Sa MF, da Silva E. Effect of low-dose combined oral contraceptive on aerobic capacity and anaerobic threshold level in active and sedentary young women. *Contraception*. 2010;81(4):309–15.
40. Joyce S, Sabapathy S, Bulmer A, Minahan C. Effect of long-term oral contraceptive use on determinants of endurance performance. *J Strength Cond Res*. 2013;27(7):1891–6.
41. Lebrun CM, Petit MA, McKenzie DC, Taunton JE, Prior JC. Decreased maximal aerobic capacity with use of a triphasic oral contraceptive in highly active women: a randomised controlled trial. *Br J Sports Med*. 2003;37(4):315–20.
42. Notelovitz M, Zauner C, McKenzie L, Suggs Y, Fields C, Kitchens C. The effect of low-dose oral contraceptives on cardiorespiratory function, coagulation, and lipids in exercising young women: a preliminary report. *Am J Obstet Gynecol*. 1987;156(3):591–8.
43. Oelkers W, Helmerhorst FM, Wuttke W, Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin–angiotensin–aldosterone system in healthy female volunteers. *Gynecol Endocrinol*. 2000;14(3):204–13.